Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nasal High Flow Therapy for Bronchiolitis.
Franklin D, Miller L, Pham TM, Frampton C, Moloney S, Waugh J, Fairless S, Hobbins S, Grew S, George S, Fahy R, Morel D, Schibler A. Franklin D, et al. Among authors: morel d. J Paediatr Child Health. 2024 May 22. doi: 10.1111/jpc.16557. Online ahead of print. J Paediatr Child Health. 2024. PMID: 38775344
LymphoDose: a lymphocyte dose estimation framework-application to brain radiotherapy.
de Kermenguy F, Benzazon N, Maury P, Vauclin R, M'hamdi M, Cifliku V, Limkin E, Diallo I, Morel D, Milewski C, Clémenson C, Mondini M, Deutsch E, Robert C. de Kermenguy F, et al. Among authors: morel d. Phys Med Biol. 2024 Apr 29;69(10). doi: 10.1088/1361-6560/ad3c8d. Phys Med Biol. 2024. PMID: 38593817
Enhancing radioprotection: A chitosan-based chelating polymer is a versatile radioprotective agent for prophylactic and therapeutic interventions against radionuclide contamination.
Durand A, Borisova T, Lux F, Howard JA, Tillement A, Kuznietsova H, Dziubenko N, Lysenko V, David L, Morel D, Berbeco R, Komisarenko S, Tillement O, Deutsch E. Durand A, et al. Among authors: morel d. PLoS One. 2024 Apr 3;19(4):e0292414. doi: 10.1371/journal.pone.0292414. eCollection 2024. PLoS One. 2024. PMID: 38568898 Free PMC article.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: morel d. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner.
Laurent PA, Milic M, Quevrin C, Meziani L, Liu W, Morel D, Signolle N, Clémenson C, Levy A, Mondini M, Deutsch E. Laurent PA, et al. Among authors: morel d. J Transl Med. 2023 Oct 31;21(1):773. doi: 10.1186/s12967-023-04619-0. J Transl Med. 2023. PMID: 37907934 Free PMC article.
378 results